Pembrolizumab
3475-564
Phase 3 mab completed
Quick answer
Pembrolizumab for Renal Cell Carcinoma is a Phase 3 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Renal Cell Carcinoma
- Phase
- Phase 3
- Modality
- mab
- Status
- completed